Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?

Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?

Hormone receptor-positive (HR+) breast cancer (BC) accounts for about 60–70% of all diagnosed BCs, and endocrine therapy has long been the hallmark of systemic treatment for this tumor subtype. However, the therapeutic paradigm of luminal BC has been overcome due to recent evidence of antibody–drug...

Full description

Bibliographic Details
Main Authors: Pierluigi De Santis, Valeria Sanna, Martina Perrone, Chiara Guarini, Anna Natalizia Santoro, Carmelo Laface, Daniela Carrozzo, Gaia Rachele Oliva, Alessandro Fancellu, Palma Fedele
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Journal of Clinical Medicine
Subjects:
HR+ breast cancer
ADCs
target therapy
HER2
combination therapy
trastuzumab deruxtecan
Online Access:https://www.mdpi.com/2077-0383/12/23/7325

Internet

https://www.mdpi.com/2077-0383/12/23/7325

Similar Items